Last reviewed · How we verify

NCT03302312

Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Acceptability

Completed Last updated 30 July 2018
What this trial tests

trial in Posttraumatic Stress Disorder in 54 participants. Completed in 2 March 2018.

Timeline
3 November 2017
Primary endpoint
2 March 2018
2 March 2018

Quick facts

Lead sponsorRTI International
StatusCompleted
Study typeOBSERVATIONAL
Enrollment54
Start date3 November 2017
Primary completion2 March 2018
Estimated completion2 March 2018
Sites3 locations across United States, Germany

Conditions studied

Sponsor

RTI International — full company profile →

Who can join

18 and older, any sex, with Posttraumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This qualitative study will use focus groups, small group interviews, and individual interviews (both in person and over the phone) to compile a range of perspectives on service members' decision-making processes and information needs related to Stellate Ganglion Block (SGB). Participants will include service members, spouses, and providers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Posttraumatic Stress Disorder

Currently open trials in the same condition.

Other RTI International trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03302312.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing